Clinical bottom line
Microbiome-targeted therapies represent a promising adjunctive approach in managing autoimmune diseases by modulating host immune responses through gut microbial composition and function. Current evidence suggests potential benefits in disease activity and symptom control, but clinical data remain preliminary and heterogeneous. Integration of microbiome modulation with established immunotherapies warrants cautious optimism pending robust, controlled trials.
What the evidence shows
The gut microbiome plays a critical role in immune system regulation, influencing the pathogenesis of autoimmune diseases. Jain et al. (2025) provide a comprehensive review of microbiome-targeted therapies, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, highlighting their mechanistic rationale and emerging clinical data.
Mackay and colleagues (2020) emphasize the interplay between diet, gut microbiota, and autoimmunity, noting that dietary modulation can alter microbial metabolites that impact systemic inflammation and immune tolerance.
Tanaka et al. (2024) discuss molecular targeted therapies in systemic autoimmune diseases, acknowledging microbiome modulation as an adjunct to biologics and small molecules, potentially enhancing therapeutic efficacy and reducing adverse effects.
Eming et al. (2011) review targeted therapies in autoimmune skin disorders, underscoring the potential for microbiome manipulation to complement immunomodulatory treatments.
Ghalamghash et al. (2025) provide a patient-centric evidence review of microbiome-targeted therapies in acne, illustrating translational relevance to other immune-mediated skin conditions.
Earlier foundational perspectives by Chatenoud et al. (2006) and Wha et al. (2012) highlight the evolving landscape of emerging therapies, including microbiome approaches, in autoimmune disease management.
Caveats and uncertainty
Clinical trials of microbiome-targeted therapies are often limited by small sample sizes, heterogeneous populations, and variable endpoints.
Long-term safety and durability of response remain unclear.
Optimal microbial strains, dosing regimens, and patient selection criteria are not well established.
Interactions with concurrent immunotherapies require further study.
Regulatory and standardization challenges persist for interventions like FMT.
How this may change practice
Clinicians should recognize the microbiome as a potential modifiable factor in autoimmune disease pathogenesis and management.
Adjunctive use of probiotics or dietary modification may be considered, particularly in patients interested in integrative approaches, while emphasizing current evidence limitations.
Ongoing and future well-designed clinical trials will clarify the role of microbiome-targeted therapies and inform guidelines.
Multidisciplinary collaboration including immunologists, gastroenterologists, and dietitians may optimize patient care.
Personalized medicine approaches incorporating microbiome profiling could emerge as a future standard.